Clinical & Commercial Solutions
Akrivia partners with pharmaceutical partners to support:
- Research & Development
- Regulatory
- HEOR & Market Access
- Pharmacovigilance & Medical Affairs
Engage earlier and more effectively with patients, sites and investigators by leveraging our Real-World Data and Live Data Access (RLDA) platform.
Research & Development
- Patient stratification and cohort design
- Defining target populations and unmet needs
- Trial feasibility studies
- Data-driven protocol design
- Synthetic control arms
- Real-world data access (RLDA) platform with live cohort exploration
- Comparator of competitor treatments
Regulatory Approval
- Natural history of disease
- Treatment patient pathway validation
- Unmet needs
- Identify suitable comparators
- External control arm
HEOR / Market Access
- Burden of disease
- Cost-effectiveness / value-based pricing
- Health Technology Assessments (HTAs)
- External control arm (addressing varying standards of care)
- Health outcomes – diverse, real patient populations
Pharmacovigilance and
Medical Affairs
- Label expansions (new indications for approved drugs)
- Post-approval safety monitoring
- Risk-benefits over time
Key Offerings:
Patient Identification & Recruitment Support
- Identify eligible patients based:
- on disease phenotypes
- treatment history
- and biomarker data to optimize recruitment strategies.
Patient Cohort Characterisation
- Define richly phenotyped patient cohorts:
- for clinical trials
- or real-world studies to support target product profile (TPP) validation and protocol design.
TPP Optimisation with RWE
- Validate and refine Target Product Profiles:
- against real-world patient journeys
- Outcomes
- and treatment landscapes.
Natural History Studies
- Undertake retrospective and prospective natural history studies:
- to characterise the patient pathway
- understand the natural progression of a disease
- diagnosis and treatment and clinical pathways
Single Arm and Synthetic Control Studies
- Support clinical trial innovation through:
- the design and setup of single-arm trials with RWE-derived comparator cohorts.
Health Technology Assessment (HTA) and Market Access
- Generate evidence:
- to inform payer value propositions,
- cost-effectiveness models
- and submissions to HTA bodies.
Post-Marketing Surveillance & Longitudinal Tracking
- Monitor:
- Safety
- Effectiveness
- and adherence in real-world populations post-launch.